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Abstract
Aneurysmal bone cyst (ABC), once considered a reactive lesion, has been proven to be a neoplasia characterized by
rearrangements of the USP6-gene. Aggressive local growth and recurrences are common and therapeutic options
may be limited due to the vicinity of crucial structures. We describe a case of a locally aggressive, multinucleated
giant cell-containing lesion of the forearm of a 21-year old woman, treated with denosumab for recurrent, surgically
uncontrollable disease. Under the influence of this RANKL inhibitor, the tumor showed a marked reduction of
the content of the osteoclastic giant cells and an extensive metaplastic osteoid production leading to the bony
containment, mostly located intracortically in the proximal radius. The diagnosis of a periosteal ABC was confirmed
by FISH demonstrating USP6 gene rearrangement on the initial biopsy. Function conserving surgery could be
performed, enabling reconstruction of the affected bone. Inhibition of RANKL with denosumab may offer therapeutic
option for patients not only with giant cell tumors but also with ABCs.
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Background
Aneurysmal bone cysts (ABCs) are rare benign skeletal
tumors usually occurring in the first two decades of life
and typically associated with a growing mass, swelling,
pain and bone destruction [1,2]. Approximately 70% of
the cases are considered primary lesions and the re-
maining 30% arising secondary to different primary tu-
mors such as osteoblastoma, giant cell tumor of bone,
chondroblastoma, fibrous dysplasia or low grade in-
tramedullary osteosarcoma [3]. It has been shown that
primary ABCs, initially considered to be reactive and
non-neoplastic [1,4], correspond to a neoplastic disor-
der associated with a specific set of genetic aberrations
[5,6]. Over the past few years many different translo-
cations have been described in ABCs, all resulting in
oncogenic activation of the USP6 gene localized to
17p13 [7-9].
Primary ABCs can affect any bone. Usually they arise
in the metaphysis of long bones such as the femur, tibia
and humerus; however, the spine may also be affected
with compression/infiltration of nerves and spinal cord
causing neurological symptoms [10]. The magnetic res-
onance imaging (MRI) demonstrates an intraosseous,
expansile, lytic, eccentric, septated lesion, containing cha-
racteristic fluid-fluid levels, except for rare solid ABC
variants. Rarely, the ABC is localized on the surface
of the long bones [11]. Histopathologically, the lesions
are composed of hemorrhagic tissue with cavitary spa-
ces separated by fibrous septa composed of spindle cells,
inflammatory cells and a smaller percentage of giant
cells [12]. Treatment options are intralesional curettage
followed by bone grafting, in combination with cryo-
therapy, sclerotherapy, radionuclide ablation, arterial
embolization and en bloc resection [13,14]. Complica-
tions associated with curettage are related to an incom-
plete resectability of the lesion resulting in recurrence
in at least 20% [2]. Clinically [15], ABCs can be divided
into inactive, active and aggressive lesions with aggres-
sive tumors expanding rapidly, destroying surrounding
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tissue and having a high rate of local recurrences. New
therapeutic options are needed for the management of
this locally aggressive disease.
Denosumab, a monoclonal antibody specifically bind-
ing RANK-ligand, inhibits bone resorption and, there-
fore, [16-18] is used in the treatment of osteoporosis,
skeletal complications of metastatic disease, and more
recently in the treatment of giant cell tumors of bone,
with a high rate of clinical success [19]. To date, we are
aware of only one publication presenting the application
of denosumab in two cases of spinal ABCs [20]. Both pa-
tients (an 8-year old boy and an 11-year old boy) recov-
ered significantly from pain and neurological symptoms.
MRI follow-up after two to four months of denosumab
therapy showed tumor regression in both patients. We
report a case of a locally aggressive periosteal ABC with
a confirmed rearrangement of USP6 arising in the radius
of a 21-year old woman with an impressive local re-
sponse to denosumab treatment and a follow-up of four
years.
Case presentation
A 21-year old right-handed woman presented with a
variable swelling and shooting pain in her right proximal
forearm in May of 2009. Clinical examination showed
a palpable swelling over the radial head mainly lo-
cated over the biceps tendon and a supination defi-
ciency. MRI revealed an extensive, deep seated, solid
soft tissue tumor with contrast uptake, infiltration of
the intra-osseous membranes, biceps tendon, contact
with the neurovascular bundle, infiltration of the supi-
nator muscle and deep extensor as well as deep flexor
muscles (Figure 1A, B). Computer tomography (CT)-
guided core-needle biopsy was performed with a clin-
ical suspicion of Ewing sarcoma. A low-grade, giant
cell-containing lesion with focal metaplastic bone for-
mation and infiltration of the skeletal muscle was diag-
nosed on histopathological examination (Figure 2A).
No necrosis, atypia or pathologic mitotic activity was
noted. The osteoclastic giant cells were numerous and
contained up to over 50 nuclei.
D (July 2011)
A (May 2009) B (2009)
C (Feb 2011)
Figure 1 Imaging of the patients right forearm tumor. (A) Initial magnetic resonance imaging (MRI) demonstrating extensive involvement of
the soft tissue between the radius and ulna as well as the cortex of the radius by an exclusively solid tumor mass (arrows). (B) Pre-treatment
computer tomography (CT) scan with a small area of a split and disrupted cortex of the radius (arrows). (C) MRI directly prior to denosumab
therapy with a locally progressive, extensive soft tissue mass following local surgical therapy 18 months previously. Fluid-fluid levels may be seen
at this point (arrow). (D) CT scan following five months of denosumab therapy demonstrating almost complete containment of the soft tissue
mass by a boney rim (arrow).
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Surgical therapy two months later consisted of a curet-
tage through an antero-lateral and dorsal incision with
dissection of the radial nerve branches to preserve ma-
ximal function. Histology of the recovered fragmented
tumor revealed similar results to the biopsy (Figure 2B)
rendering the diagnosis of an incompletely resected giant
cell tumor of soft tissue. Residual tumor has been fol-
lowed clinically and on imaging with a new local pro-
gression noticed at the end of 2010. MRI in February
2011 (Figure 1C) showed a significant increase in the
size of a recurrent and progressively symptomatic tumor.
Under the assumption of the diagnosis of a giant cell
tumor of soft tissue, the therapy with denosumab (120 mg
subcutaneously injected every month) for four months
was administered with no untoward side effects. Follow-
up MRI after one month of denosumab showed ob-
vious tumor regression in size. Five months after the
first denosumab injection, surgery was performed (July
2011). As a result of good treatment response, the tu-
mor had become significantly better circumscribed
and clearly demarcated by a bony rim (Figure 1D), lea-
ding to the feasibility of a complete resection of the
tumor. Reconstruction was performed using an intercal-
ary fibula-allograft with 3D planning to adjust for radial
head rotation and a custom-made plate (Figure 3A). The
gross examination of the resection specimen (Figure 3B)
revealed an extensive, almost circumferential, intracor-
tical bone tumor mass extending over 4.4 cm of the di-
aphysis of the radius with a small intramedullary nodule
proximally and an intracortical satellite lesion distally.
The histology of the post-treatment tumor specimen
(Figure 2C, D) differed in comparison to the material
of the core biopsy and curettage (Figure 2A, B) showing
markedly reduced numbers of osteoclasts. The individual
giant cells contained only few nuclei. Few small, pseudo-
cystic spaces were observed in the background of collagen
rich connective tissue, containing bland mononuclear
cells. There was pronounced metaplastic new bone pro-
duction with extensive areas of so-called ‘blue bone’ and
lamellar cortical bone at the periphery of the lesion (aste-
risk Figure 2C). Due to the gross findings with almost
exclusive intracortical tumor location, the lesion was re-
classified as a predominantly intracortical, aneurysmal
bone cyst of the proximal radius. Bone and soft tissue
resection margins were free of tumor except for an un-
clear area at the distal corticalis.
At first presentation in 2009, most of the exclusively
solid tumor mass was localized in the soft tissues of the
A (2009) B (2009)
C (July 2011) D (July 2011)
RANK
Figure 2 Histopathology of the pre- and post-treatment tumor tissue specimen. (A) Pre-treatment biopsy sample showing giant cell
containing soft tissue mass with extensive infiltration of the skeletal muscle (H&E stain; original magnification 50×). (B) Abundant lesional giant
cells with numerous nuclei and mononuclear cells in the background (H&E stain; original magnification 100×). Inset shows immunohistochemical
expression of RANK (dilution 1:400; R&D Systems, Abingdon, United Kingdom) by the osteoclastic giant cells. (C) Denosumab treatment induced
boney containment (asterisk) of the tumor (upper left) (H&E stain; original magnification 25×). (D) Post-denosumab-treatment tumor specimen
showing pronounced reduction of the number of giant cells (H&E stain; original magnification 100×).
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forearm on imaging (Figure 1A), leading to the diagnosis
of giant tumor of soft tissue. Retrospectively, careful
analysis of the initial CT scans (Figure 1B) showed an
area of split and disrupted cortical bone of the radius,
which might have initially suggested the diagnosis of an
intracortical (solid variant) ABC with a massive exten-
sion to the periosteal tissue. Finally, the diagnosis of a
primary ABC was definitively confirmed by demons-
tration of a rearrangement of the USP6 gene locus by
fluorescence in situ hybridization (FISH) as described
previously [21], utilizing a custom-designed break apart
probe set on the original biopsy sample (Figure 4). The
mononuclear nuclei exhibit one fused red/green signal
corresponding to a normal 17p USP6 locus (black arrow)
and a pair of split green and red signals (white arrows) in-
dicating a rearrangement of the USP6 locus consistent
with the diagnosis of aneurysmal bone cyst.
Further follow up was unremarkable for another 19
months until a control MRI in February 2013 revealed
a small (< 1 cm) lesion in the area of the distal osteotomy
and the core biopsy confirmed the local recurrence of the
ABC, which is currently being treated with denosumab.
Conclusion
In this report, we describe a patient treated with denosu-
mab for a locally aggressive, presumed giant cell tumor
of soft tissue of the forearm. Evaluation of the resection
specimen led to the final diagnosis of an intracortical
aneurysmal bone cyst with massive infiltration of the
soft tissue, a diagnosis which was also confirmed by
FISH analysis.
Histopathologic differential diagnosis of osteoclastic
giant cell containing lesions of skeletal tissues is exten-
sive (giant cell tumor of bone, giant cell tumor of soft
tissue, tenosynovial giant cell tumor, aneurysmal bone
cyst, reparative giant cell granuloma, brown tumor of
hyperparathyroidism, non-ossifying fibroma) and the
final diagnosis has to be made in close conjunction
B
A
Figure 3 Resection of the shaft of the proximal radius following the denosumab therapy. (A) Reconstruction using an intercalary
fibula-allograft and a custom-made plate. (B) Longitudinal section of the resected specimen demonstrating large intracortical, fully
contained by a rim of bone tumor mass (asterisk) with a small intramedullar tumor nodule proximally (black arrow) and an intracortical
satellite distally (white arrow).
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with clinical and radiological information. Giant cells
occurring in both giant cell tumors (GCTs) and in
ABCs are positive for markers of true osteoclasts, ex-
pressing RANK (receptor activator of NF-κB) and pro-
moting bone destruction [22]. The formation of osteoclast
type of giant cells in the GCTs is considered to be a conse-
quence of the local production of RANKL (RANK-ligand)
by the mononuclear, true neoplastic tumor cells [23]. A
current therapeutic option for patients with giant cell tu-
mors of bone is curettage with optimal preservation of
function. However, patients undergoing curettage often
have recurrent disease or significant morbidity. Denosu-
mab is a human anti-RANKL monoclonal antibody that
inhibits RANKL function and therefore its osteoclast ac-
tivity, and causes the repression of osteoclast recruitment,
maturation and bone resorption [16,18]. Denosumab is
a Food and Drug Administration (FDA)-approved drug
for osteoporosis and skeletal-related events in patients
with bone metastases. A study to explore the action
of denosumab in the treatment of giant cell tumor of
bone was performed [19], demonstrating that the de-
nosumab treated patients had a decrease in giant cells
of 90 percent or greater, an indicator for the reduc-
tion of the aggressiveness of the tumors. The applica-
tion of denosumab for bone tumors other than GCT
has rarely been investigated. There exists only one report
of denosumab use for ABC in two patients with spinal tu-
mors [20]. However, the molecular confirmation of the
primary ABCs as well as the histologic changes observed
during and following therapy has not been previously
reported.
Denosumab therapy was well tolerated by the cur-
rent patient. The impressive positive treatment effects
on the tumor tissue, as illustrated by marked reduc-
tion in the number of giant cells, were coupled with
the bony demarcation of the tumor and facilitated sub-
sequent function preserving surgery. The application of
this form of the RANKL inhibition led to the transition
of a locally aggressive and destructive tumor into a
resectable lesion, thus preserving full function in our
patient.
Our observations support the hypothesis that not only
patients with GCTs, but also those suffering from ABCs
may benefit substantially from RANKL-inhibiting deno-
sumab treatment. These findings may offer new thera-
peutic options for often young patients with these locally
aggressive tumors, especially in uncontrollable, locally
destructive or recurrent disease.
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Figure 4 Fluorescence in situ hybridization conducted on the
pretreatment specimen with a custom-designed break apart
probe set; the probe cocktail proximal to the USP6 locus is
labeled in green and distal in red. The mononuclear nuclei
exhibit one fused red/green signal corresponding to a normal 17p
USP6 locus (black arrow) and a pair of split green and red signals
(white arrows) indicating a rearrangement of the USP6 locus
consistent with the diagnosis of aneurysmal bone cyst.
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